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Introduction
Hepatocellular carcinoma (HCC) is the sixth most
common cancer worldwide, but because of the poor
prognosis associated with this disease, it is the third
most common cause of cancer-related death (1).
Over 80% of patients with HCC are in developing
countries, with particularly high incidence rates in
sub-Saharan Africa and Southeast Asia (1). There is
a low incidence of HCC in developed countries such
as the USA, Australia and the UK, but these rates are
rising (2).
Risk factors for the development of HCC have
been well documented and include the presence of
cirrhosis, infection with hepatitis B and C viruses,
heavy alcohol intake, diabetes and obesity (1,2).
Although surveillance and vaccination programmes
have reduced the incidence of HCC in certain popu-
lations (3,4), the majority of patients still present
with unresectable disease and are unsuitable for sur-
gery. Current treatments for unresectable disease
include loco-regional interventions and systemic
therapies, although further data on all treatments are
required to fully understand their potential, e.g. in
patient groups not included in clinical trials.
Non-surgical loco-regional treatment options
include ablation therapy and transarterial chemo-
embolisation (TACE). Ablation therapy is associated
with a 5-year survival rate of 40–70%, with best
responses seen among patients with single tumours
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SUMMARY
Background: Hepatocellular carcinoma (HCC) is a complicated condition influ-
enced by multiple confounding factors, making optimum patient management
extremely challenging. Ethnicity, stage at diagnosis, comorbidities and tumour mor-
phology affect outcomes and vary from region to region, and there is no common
language to assess patient prognosis and make treatment recommendations.
Despite recent efforts to reduce the incidence of HCC, most patients present with
unresectable disease. Non-surgical treatments include ablation, transarterial chemo-
embolisation and the multikinase inhibitor, sorafenib, but their effects in all patient
subgroups are not known and further information is needed to optimise the use of
these treatments. Aims: The Global Investigation of Therapeutic DEcisions in
Hepatocellular Carcinoma and Of its Treatment with SorafeNib (GIDEON) study
(ClinicalTrials.gov identifier NCT00812175; http://clinicaltrials.gov/) is an ongoing
global, prospective, non-interventional study of patients with unresectable HCC
who are eligible for systemic therapy and for whom the decision has been taken
to treat with sorafenib under real-life practice conditions. The aim of this study is
to evaluate the safety and efficacy of sorafenib in different subgroups, especially
Child-Pugh B where data are limited. Discussion: This study will recruit 3000
patients from > 40 countries and follow them for approximately 5 years to com-
pile a large and robust database of information that will be used to analyse local,
regional and global differences in baseline characteristics, disease aetiology, treat-
ment practice patterns and treatment outcomes, with a view to improve the
knowledge base used to guide physician treatment decisions and to improve
patient outcomes.
What’s known
• HCC is a complex disease influenced by multiple
confounding factors that vary from region to
region, making optimum patient management
extremely complex.
• Sorafenib is an oral multikinase inhibitor with
proven efficacy in patients with unresectable
HCC, but data in Child-Pugh B are limited.
• There is a need to fully evaluate existing
treatments in all patient subgroups to optimise
their use.
What’s new
• GIDEON will generate data from 3000 patients
to evaluate the effects of sorafenib in different
patient subgroups, and the resulting large
database will be used to analyse local, regional
and global differences that influence patient
prognosis and management, with a view to
refine HCC staging and evaluation and better
inform treatment decisions
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and preserved liver function (5). However, TACE is
recommended for patients with large ⁄multifocal
tumours with no vascular invasion or extra-hepatic
spread and is associated with objective response rates
of 16–60% (3). Although survival benefits have been
reported in only two randomised controlled trials
(RCTs) (6,7), a robust meta analysis showed that the
treatment with TACE was associated with significant
improvements in 2-year survival vs. control (8).
However, TACE treatment has a number of impor-
tant limitations. Residual tumour growth following
treatment means that treatment repetition is neces-
sary. Additionally, many of the clinical studies inves-
tigating TACE have used a wide range of treatment
strategies, including different types of embolic parti-
cle, chemotherapy, emulsifying agent and numbers of
treatment sessions. For this reason, there is no clear
evidence to support an optimum treatment strategy
(9). Also, TACE therapy is only possible in patients
where the arterial blood supply to the tumour can be
isolated, and is not recommended in patients with
portal vein thrombosis, those with Child-Pugh C
liver function or those with a total serum bilirubin
level > 3 mg ⁄ml, as all of these factors have been
identified as predictors of poor prognosis in patients
treated with TACE (9). Finally, treatment with TACE
is associated with considerable side effects; the most
commonly reported being postembolisation syn-
drome that occurs in > 50% of treated patients (3).
Other less frequent but more serious complications
include hepatic abscess and cholecystitis. Further
research is therefore needed to optimise TACE
treatment strategy and ensure treatment efforts are
directed at patients who will most likely benefit.
Systemic therapies investigated for unresectable
HCC have included single-agent and combination
chemotherapy regimens, but their efficacy has been
disappointing and their use is no longer recommended
(9). More recently, the Sorafenib HCC Assessment
Randomized Protocol trial, a multicentre, Phase III,
double-blind, placebo-controlled trial of 602 Western
patients with unresectable HCC, showed that treat-
ment with the oral multikinase inhibitor, sorafenib
(Nexavar; Onyx Pharmaceuticals, Inc., Emeryville,
CA, USA; Bayer HealthCare Pharmaceuticals, Inc.,
Wayne, NJ, USA; Bayer Schering Pharma AG, Berlin,
Germany), was associated with a significant improve-
ment in survival compared with placebo [median
overall survival (OS) of 10.7 months vs. 7.9 months
for sorafenib and placebo respectively, p < 0.001]
(10). As a result, sorafenib is the first systemic antican-
cer therapy indicated for treating these patients (9).
Similar benefits (median OS of 6.5 months vs.
4.2 months for sorafenib and placebo respectively,
p = 0.014) were reported in a Phase III, randomised,
double-blind, placebo-controlled trial of 226 patients
with unresectable HCC from the Asia-Pacific region,
thus confirming the efficacy of sorafenib in a broad
geographic patient population (11). However, all
patients included in these two large RCTs had pre-
served liver function (Child-Pugh A), and our knowl-
edge regarding the efficacy of sorafenib in patients
with hepatic impairment is limited to small subgroups
of patients from Phase I and II studies (12,13). Further
studies to evaluate the efficacy of sorafenib among all
patient groups are therefore needed.
Current treatment guidelines for unresectable
disease are therefore based on the best available
evidence, including non-randomised trials, case
studies and expert opinion; however, significant data
gaps exist. Further evidence is needed to fully evalu-
ate current treatment options and optimise their use
to improve patient outcomes.
Against this background, the Global Investigation of
Therapeutic DEcisions in Hepatocellular Carcinoma
and Of its Treatment with SorafeNib (GIDEON) study
is an ongoing global, non-interventional study (NIS)
of patients with unresectable HCC who are to receive
sorafenib as part of their standard clinical care. The
study should produce the largest, most robust
database of information on factors influencing
treatment and outcome of patients with HCC. This
manuscript will include details of the GIDEON aims
and objectives, study design, target recruitment and
timeline. It will also describe the planned analyses and
discuss how it is hoped that findings from this study
will allow us to gain a detailed understanding of the
factors that influence the prognosis and management
of these patients, and how this in turn will help us to
refine HCC staging and evaluation, better inform
treatment choices and ultimately improve outcomes
for patients with HCC.
The GIDEON study
Aims, objectives and rationale for GIDEON
Non-interventional studies, or observational studies,
are postauthorisation safety studies (PASS) that are
usually conducted to gain further information about
a licensed product. Observational studies are charac-
terised by the fact that assignment to a particular
therapy strategy is not mandated by a study protocol
but reflects the participating physician’s current prac-
tice. The physician alone decides which treatment, if
any, is appropriate. In NIS, the decision to include a
patient in a study is separate from the treatment
decision. Furthermore, no additional diagnostic or
monitoring interventions are mandated for the
patient as a result of inclusion in an NIS. NIS serve
a wide range of purposes but are of particular value
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in providing information in wider populations or
subgroups not covered in RCTs (14). NIS also enable
information to be gathered on other parameters not
usually assessed in the clinical trial setting, such as
patient acceptance and compliance, physician adher-
ence to information and directions for use and pre-
scription behaviour. The importance of NIS in the
literature is increasingly recognised, and guidelines
were developed to improve the analysis and report-
ing of observational studies (15). NIS provide oppor-
tunities to enhance the evidence base for established
drugs and therapies and increase understanding of
the impact of treatments in real-world practice (14).
GIDEON is a global, prospective NIS of patients
with unresectable HCC who are candidates for sys-
temic therapy and for whom the decision has been
taken to treat with sorafenib. It was initiated to fulfil
the postapproval commitment to organisations such
as the European Medicines Agency to gather data on
the safety and efficacy of sorafenib in patients with
Child-Pugh B liver function. Additional goals are to
compile a large and robust database of HCC treat-
ment patterns and outcomes among patients with
unresectable disease who are candidates for systemic
therapy, to answer clinically relevant questions and
gain a better understanding of the safety of sorafenib
with loco-regional therapies, given either concomi-
tantly or sequentially. Data will also be gathered in
the USA and possibly other regions on the character-
istics, disease course and treatment outcomes of
patients with newly diagnosed HCC or recurring dis-
ease after curative treatments, who are not candidates
for systemic therapy with sorafenib.
Based on these goals, the primary objective of
GIDEON is to evaluate the safety of sorafenib in
patients with unresectable HCC in real-life practice
conditions. Secondary objectives are to: evaluate the
efficacy [OS, progression-free survival (PFS), time to
progression (TTP), response rate and stable disease
rate] of sorafenib in these patients; determine the
duration of therapy according to various patient
characteristics; evaluate methods of patient evalua-
tion, diagnosis and follow-up; assess comorbidities
and their influence on treatment and outcome in
real-life practice rather than a controlled clinical trial
setting and evaluate the practice patterns of the phy-
sicians involved in the care of these patients.
This study was conducted according to established
regulations and recommendations relating to the
conduct of NIS; volume 9A of the Rules Governing
Medicinal Products in the European Union (16).
When required, documented approval from the
appropriate ethics committee(s) ⁄ institutional review
board was obtained for all participating centres prior
to the study, according to Good Clinical Practice and
local laws, regulations and organisations.
Establishing a global NIS
GIDEON is a Phase IV, international, prospective,
open-label, multicentre, non-interventional PASS of
patients with unresectable HCC receiving sorafenib
under real-life conditions. Approximately, 3000 eligi-
ble patients will be recruited by participating physi-
cians from > 40 countries across Europe, Latin
America and the Asia-Pacific region and from the
USA (Figure 1) and will be observed from the start
Figure 1 The global reach of GIDEON
1036 The non-interventional GIDEON study
ª 2010 Blackwell Publishing Ltd Int J Clin Pract, July 2010, 64, 8, 1034–1041
of sorafenib therapy to patient withdrawal, loss to
follow-up, death or final visit.
An overview of the GIDEON timeline and planned
analyses is shown in Figure 2. The first patient’s first
visit was recorded in January 2009 and the last
patient’s first visit is anticipated to occur in quarter
four of 2012. Interim analyses for safety will be con-
ducted after 500 and 1500 patients have been recruited
and followed for 4 months, with the final analysis
anticipated in quarter two or three of 2014. The study
will end 12 months after enrolment of the 3000th eli-
gible patient, irrespective of whether the final patient
dies or not, is lost to follow-up or survives.
Patients to be included in GIDEON
Patients with histologically or cytologically docu-
mented or radiographically diagnosed unresectable
HCC who are candidates for systemic therapy, and
for whom a decision has been made to treat with
sorafenib, are eligible for inclusion in GIDEON if
they have a life expectancy of > 8 weeks and have
provided signed informed consent. Patient exclusion
criteria are based on the approved local product
information for sorafenib.
Data collection
All data will be collected using case report forms
(CRFs). These will be available as paper and elec-
tronic versions, with participating countries and their
sites able to choose the format of preference. Data
will be collected from all enrolled patients at study
entry and start of sorafenib, then at intervals nor-
mally used by the prescribing physician (estimation:
‡ 6 to £ 12 weeks), or until patient death, with-
drawal or loss to follow-up, or if significant changes
in a patient’s disease are observed. All data will be
verified through spot site monitoring, which will take
place at up to 10% of all sites involved in the study.
An overview of the visit schedule and data collected
at each visit is shown in Figure 3. Study end-points
are summarised in Figure 4. All adverse events (AEs)
will be graded according to the National Cancer
Institute Common Terminology Criteria version 3.0
(National Cancer Institute, Bethesda, MD, USA), and
their likely relationship to sorafenib therapy will be
documented. Tumour assessments will be made by
computed tomography or other equivalent radio-
graphical method and will be evaluated using the
Response Evaluation Criteria in Solid Tumors.
The population of patients who entered this study
and received at least one dose of sorafenib will be
valid for intent-to-treat safety and efficacy analysis.
However, patients who received sorafenib in the past
will be excluded from efficacy analysis. All baseline
demographic data will be summarised for the intent-
to-treat population. AEs and other safety parameters,
including blood pressure, Child-Pugh grade and
Eastern Cooperative Oncology Group performance
status (ECOG PS), will be summarised using the
safety population.
Planned subgroup analyses conducted globally,
regionally and by country will include: the impact of
baseline characteristics on safety, particularly Child-
Pugh B; the relationship between baseline character-
istics and efficacy; the duration of sorafenib therapy
and reasons for discontinuation; the effect of other
treatments for HCC on outcome and the impact of
different practice patterns on outcome. In addition,
subgroup analyses for specific regions may be con-
ducted, such as: an evaluation of common treatments
for HCC in Asia; referral and diagnostic patterns in
Europe; duration of treatment, tolerability and com-
pliance in Latin America and patient selection for
loco-regional therapy in Japan. However, all sub-
group analyses performed will depend on the actual
data collected.
Statistical considerations for GIDEON
An overall sample size of 3000 patients with unresec-
table HCC treated with sorafenib is expected to be
Figure 2 An overview of the GIDEON timeline and planned analyses
The non-interventional GIDEON study 1037
ª 2010 Blackwell Publishing Ltd Int J Clin Pract, July 2010, 64, 8, 1034–1041
sufficient to allow for evaluation of safety of the
overall population as well as specific subgroups. With
this sample size, there would be an 84% chance of
observing an AE with a true incidence of 1% in at
least 25 patients.
All baseline, safety and efficacy data were analysed
using descriptive statistics. Kaplan–Meier estimates
were calculated for the OS, PFS and TTP efficacy
end-points. At the time of the analyses, any patient
alive or lost to follow-up, without disease progres-
sion or death or without documented radiological
progression will be censored at the last date of evalu-
ation for OS, PFS and TTP analyses, respectively.
Exploratory subgroup analyses of efficacy and safety
data may also be performed, stratified by prognos-
tic ⁄predictive baseline factors such as stage, Child-
Pugh score, ECOG PS, region and age, as appropri-
ate. Data regarding administration of sorafenib such
as duration, given dose, continuation or discontinua-
tion of therapy and dose modification of sorafenib
therapy, including reason(s) for discontinuation, will
be summarised in a descriptive manner. Treatments
for HCC other than sorafenib before, during and
after therapy with sorafenib will be summarised
descriptively as per available data. The sample size
was calculated to collect data to allow for sufficient
BCLC, Barcelona Clinic Liver Cancer; CLIP, Cancer of the Liver Italian Program; ECOG PS, Eastern
Cooperative Oncology Group performance status; HCC, hepatocellular carcinoma; NCI-CTC, National
Cancer Institute-Common Toxicity Criteria; OS, overall survival; PFS, progression-free survival;
RR, response rate; SD, stable disease; TNM, tumour node metastases; TTP, time to progression
Figure 4 Overview of the GIDEON safety, efficacy, treatment and baseline patient assessments and end-points
Figure 3 GIDEON patient assessment schedule
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evaluation of safety monitoring of all treated
patients. Interim analyses are planned during the
study primarily for summarising and monitoring
safety data, and will be conducted after 500 patients
and 1500 patients are enrolled and have been treated
on study for at least 4 months.
Discussion
What will GIDEON achieve?
GIDEON is a global PASS initiated to collect more
information on the safety and efficacy of sorafenib in
patients with unresectable HCC. This is the largest
prospective HCC NIS in the world, which will enrol
3000 patients from > 40 countries globally. The com-
pilation of a database of this size in HCC has not pre-
viously been undertaken; as no other global registries
exist in this area, it is anticipated that the data col-
lected here will be an important contribution to our
knowledge and will help to answer important and
clinically relevant questions relating to the natural
disease course of HCC and liver dysfunction, long-
term efficacy and safety of sorafenib therapy, physi-
cians’ practice patterns and patients’ perspectives.
The number of factors influencing HCC and its
disease course make it extremely difficult to accu-
rately assess patient prognosis and make optimum
treatment recommendations. The geographical varia-
tion of these factors has also prevented the establish-
ment of a universal system to assess all patients.
Findings from GIDEON could help to establish a
globally applicable staging classification, which could
facilitate the accurate and consistent assessment of all
patients and help to provide a common language for
the broad HCC multidisciplinary team on which to
base treatment recommendations. In addition, as
GIDEON will collect data regarding the differences in
physician treatment practice patterns and outcomes,
it may be possible to analyse these data with a view
to optimise the role of all members of this large
multidisciplinary team and streamline patient care.
Although potentially curative therapy via surgical
resection or transplant is possible for some patients
with HCC, there is a lack of cadaveric transplants
available, and the majority of patients are unsuitable
for surgery at presentation. In addition, the recur-
rence rate of HCC after curative treatment is high
and the long-term curable rate is low (17). Thus,
non-surgical treatments play a central role in the
management of these patients. However, there is still
a relative shortage of RCTs to fully evaluate these
treatments in all patient subgroups, and more work
is needed to fully understand the benefits of each of
these treatments and to establish their place in the
HCC treatment armamentarium. One of the main
focuses of GIDEON is to gain further information
on the optimum duration of sorafenib therapy as
well as the safety and efficacy of sorafenib in differ-
ent subgroups of patients, especially patients who are
generally excluded from RCTs to minimise errors or
confounding factors in the study, i.e. patients who
have moderate liver dysfunction (Child-Pugh B)
where data are currently limited. However, informa-
tion is also being gathered regarding the safety and
outcomes following other treatments before, during
and after sorafenib therapy; thus, it is anticipated
that the information gathered in this study will help
to improve our understanding of the risks and bene-
fits associated with each of these treatment
approaches, which could help us to establish an opti-
mum treatment algorithm for these patients.
In addition to GIDEON, a large clinical trial pro-
gramme for sorafenib is ongoing that should help us
to fully establish its optimum place in therapy. One
area of interest is the role of sorafenib as adjuvant
therapy to improve survival of patients with HCC.
To date, treatments such as radiotherapy and chemo-
therapy and their combination have been used to
reduce tumour size and improve patients’ quality of
life (18). TACE has recently been shown to be the
only palliative treatment that can benefit HCC
patients ineligible for curative treatments because of
advanced tumour stage or poor hepatic functional
reserve; however, the survival gain appears marginal
(19) and other effective treatments are urgently
needed. Against this background, a large Phase III,
randomised, double-blind, placebo-controlled trial of
adjuvant sorafenib following either surgical resection
or local ablation is currently in progress (STORM
study) (20). The primary end-point is recurrence-free
survival, with secondary end-points including time
to recurrence and OS. Estimated accrual to this trial
is 1100 patients and data are due to be reported
in 2014.
Another area of interest is the efficacy of sorafenib
in combination with, and subsequent to, TACE ther-
apy. A large randomised Phase II trial has been initi-
ated to evaluate the role of sorafenib in combination
with TACE in the treatment of patients with inter-
mediate disease (SPACE study) (21). Estimated
enrolment to this trial is 350 patients, and final
results are expected in late 2010. In addition to this,
a Phase III, double-blind, randomised, placebo-
controlled trial of sorafenib following TACE in
Japanese patients with unresectable, advanced disease
is ongoing (Japan post-TACE study) (22). The target
recruitment of 414 patients has already been reached
and final results are anticipated in early 2010.
Finally, the effects of sorafenib in combination
with other targeted agents in HCC are also of
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interest, and a large Phase III, randomised, double-
blind trial evaluating the efficacy, safety and health-
related quality of life of sorafenib plus erlotinib vs.
sorafenib plus placebo for the first-line treatment of
advanced HCC is in progress (SEARCH study) (23).
The target recruitment for this study is 700 patients
and the estimated final data collection date is July
2011.
These ongoing studies form a comprehensive and
well-integrated clinical trial programme, which will
provide data from several points in the treatment
pathway. GIDEON is also a key component of this
programme, as it will provide data from the entire un-
resectable patient population treated under real-life
conditions, not in a non-restrictive setting and within
the approved indication, and will enable the collection
of data from populations not commonly included in
RCTs, such as those with Child-Pugh B liver function.
Thus, in addition to the ongoing interventional
studies, the information collected in GIDEON will sig-
nificantly contribute to the current body of evidence,
which helps inform treatment decisions.
What are the limitations of GIDEON?
The information gathered in GIDEON will form a
large and robust database that will be analysed to
improve our understanding of the global, regional
and local differences in patient demographics, disease
course and treatment outcomes, with a view to
improve our knowledge base and improve patient
outcomes. However, as this is an observational NIS,
it is associated with a number of limitations. The
lack of randomisation to specific treatment arms and
the lack of a placebo-control arm will limit any
robust evaluation of the efficacy of any of the treat-
ments received by these patients during the course of
the study. Comparisons between sorafenib-treated
and untreated patients in the USA will be limited
because of the small sample size of patients in the
USA who will not receive sorafenib. The value of
some subgroup analyses may also be limited by small
patient numbers, although these analyses may still be
hypothesis-generating and could help direct future
research. However, given these limitations, it will be
important to consider findings from GIDEON
together with emerging data from large RCTs, to
fully evaluate the safety and efficacy of these treat-
ments and draw any definitive conclusions.
Another possible limitation in GIDEON is that all
data will be collected via the completion and submis-
sion of CRFs, which could delay data collection and
evaluation. However, electronic versions of the CRF
have been compiled with a view to facilitate this pro-
cess and to reduce any lengthy delays in completing
and analysing the data collected.
As with any observational study, a number of
biases may also exist. The lack of blinding of either
the treating physician or the patient to study treat-
ment may introduce a bias in reporting treatment
outcomes. It is also possible that physicians engaged
in GIDEON may be more likely to choose sorafenib
therapy for a larger proportion of their patients
than would be representative of normal treatment
practice patterns in that area, although all patients
receiving sorafenib therapy must be eligible accord-
ing to the locally approved product information for
sorafenib. Finally, while study procedures regarding
data collection and verification are in place for
GIDEON, it should be noted that in an NIS, poten-
tial exists for less robust data than might be
expected from an RCT.
Conclusions
GIDEON is the largest global, prospective, open-label
NIS ever conducted among patients with unresec-
table HCC. The study was initiated to further evalu-
ate the safety and efficacy of sorafenib in different
patient subgroups, including Child-Pugh B. The col-
lection of information regarding patient baseline
demographics, disease aetiology, treatments and
outcomes from approximately 3000 patients world-
wide, over a period of approximately 5 years, will
also enable the compilation of a large and robust
database that will be used to analyse local, regional
and global differences, with a view to answer some
important questions and fill significant data gaps. It
is therefore anticipated that findings from GIDEON,
together with data from large RCTs, will help
improve the knowledge base used to guide physician
treatment decisions and may enable physicians to
make better informed treatment choices and ulti-
mately improve patient outcomes.
Acknowledgements
The authors take full responsibility for the scope,
direction and content of the manuscript and have
approved the submitted manuscript. They would like
to thank Karen Brayshaw, PhD, at Complete Health-
Vizion for her assistance in the preparation and revi-
sion of the draft manuscript, based on detailed
discussion and feedback from all the authors.
Editorial assistance was supported by a grant from
Bayer HealthCare Pharmaceuticals.
Research funding
The GIDEON study is funded by Bayer HealthCare
Pharmaceuticals and Onyx Pharmaceuticals.
1040 The non-interventional GIDEON study
ª 2010 Blackwell Publishing Ltd Int J Clin Pract, July 2010, 64, 8, 1034–1041
Author contributions
All authors are members of the Global Steering
Committee for the GIDEON study and have been
involved in the discussion and modification of the
GIDEON protocol. All authors provided critical
review of the manuscript and approved the final
version for publication.
References
1 Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics,
2002. CA Cancer J Clin 2005; 55: 74–108.
2 El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiol-
ogy and molecular carcinogenesis. Gastroenterology 2007; 132:
2557–76.
3 Bruix J, Sherman M, Practice Guidelines Committee, American
Association for the Study of Liver Diseases. Management of hepa-
tocellular carcinoma. Hepatology 2005; 42: 1208–36.
4 Chang MH, You SL, Chen CJ et al. Decreased incidence of hepato-
cellular carcinoma in hepatitis B vaccinees: a 20-year follow-up
study. J Natl Cancer Inst 2009; 101: 1348–55.
5 Lopez PM, Villanueva A, Llovet JM. Systematic review: evidence-
based management of hepatocellular carcinoma–an updated analy-
sis of randomized controlled trials. Aliment Pharmacol Ther 2006;
23: 1535–47.
6 Lo CM, Ngan H, Tso WK et al. Randomized controlled trial of
transarterial lipiodol chemoembolization for unresectable hepato-
cellular carcinoma. Hepatology 2002; 35: 1164–71.
7 Llovet JM, Real MI, Montan˜a´ X et al. Arterial embolisation or
chemoembolisation versus symptomatic treatment in patients with
unresectable hepatocellular carcinoma: a randomised controlled
trial. Lancet 2002; 359: 1734–9.
8 Llovet JM, Bruix J, for the Barcelona-Clinic Liver Cancer Group.
Systematic review of randomized trials for unresectable hepatocel-
lular carcinoma: chemoembolization improves survival. Hepatology
2003; 37: 429–42.
9 National Comprehensive Cancer Network. NCCN Guidelines in
Oncology 2009. http://www.nccn.org/professionals/physician_gls/
f_guidelines.asp (accessed April 2010).
10 Llovet JM, Ricci S, Mazzaferro V et al. Sorafenib in advanced
hepatocellular carcinoma. N Engl J Med 2008; 359: 378–90.
11 Cheng AL, Kang YK, Chen Z et al. Efficacy and safety of sorafenib
in patients in the Asia-Pacific region with advanced hepatocellular
carcinoma: a phase III randomised, double-blind, placebo-con-
trolled trial. Lancet Oncol 2009; 10: 25–34.
12 Abou-Alfa GK, Schwartz L, Ricci S et al. Phase II study of
sorafenib in patients with advanced hepatocellular carcinoma.
J Clin Oncol 2006; 24: 4293–300.
13 Furuse J, Ishii H, Nakachi K et al. Phase I study of sorafenib in
Japanese patients with hepatocellular carcinoma. Cancer Sci 2008;
99: 159–65.
14 Ligthelm RJ, Borzi V, Gumprecht J et al. Importance of observa-
tional studies in clinical practice. Clin Ther 2007; 29 Spec No:
1284–92.
15 Vandenbroucke JP, von Elm E, Altman DG et al. Strengthening
the reporting of observational studies in epidemiology (STROBE):
explanation and elaboration. Ann Intern Med 2007; 147: W163–94.
16 European Medicines Agency. Volume 9A of the Rules Governing
Medicinal Products in the European Union. http://ec.europa.eu/
enterprise/pharmaceuticals/eudralex/vol-9/pdf/vol9a_09-2008.pdf
(accessed April 2010).
17 Spangenberg HC, Thimme R, Blum HE. Evolving therapies in the
treatment of hepatocellular carcinoma. Biologics 2008; 2: 453–62.
18 Saito H, Masuda T, Tada S et al. Hepatocellular carcinoma in Keio
affiliated hospitals–diagnosis, treatment, and prognosis of this
disease. Keio J Med 2009; 58: 161–75.
19 Shin SW. The current practice of transarterial chemoembolization
for the treatment of hepatocellular carcinoma. Korean J Radiol
2009; 10: 425–34.
20 NCT00692770. Sorafenib as Adjuvant Treatment in the Prevention
of Recurrence of Hepatocellular Carcinoma (STORM). http://
clinicaltrials.gov/ct2/show/NCT00692770?term=nct00692770&rank=1
(accessed April 2010).
21 NCT00855218. A Phase II Randomized, Double-blind, Placebo-
controlled Study of Sorafenib or Placebo in Combination With Trans-
arterial Chemoembolization (TACE) Performed With DC Bead and
Doxorubicin for Intermediate Stage Hepatocellular Carcinoma
(HCC). http://clinicaltrials.gov/ct2/show/NCT00855218?term=nct00
855218&rank=1 (accessed April 2010).
22 NCT00494299. Phase III Study of BAY 43-9006 in Japanese Patients
With Advanced Hepatocellular Carcinoma. http://clinicaltrials.
gov/ct2/show/NCT00494299?term=nct00494299&rank=1 (accessed
April 2010).
23 NCT00901901. Nexavar-Tarceva Combination Therapy for First
Line Treatment of Patients Diagnosed With Hepatocellular Carci-
noma (SEARCH). http://clinicaltrials.gov/ct2/show/NCT00901901?
term=nct00901901&rank=1 (accessed April 2010).
Paper received January 2010, accepted March 2010
The non-interventional GIDEON study 1041
ª 2010 Blackwell Publishing Ltd Int J Clin Pract, July 2010, 64, 8, 1034–1041
